chemieunternehmen.com

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-expand-ipsc-collaboration-to-include-additional-cell-lines-5733

Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-signs-agreement-with-sanofi-to-advance-early-stage-academic-research-into-novel-therapeutic-candidates-5729

MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec. The project aims to develop a novel therapeutic approach to treat glaucoma, an irreversible neurodegenerative disease of the optic nerve which can lead to blindness. This project is derived from a decade of research investigating the molecular pathways underlying tissue damage and repair in the eye in the laboratory of Dr. Jeremy Sivak, Senior Scientist at UHN’s Krembil Research Institute, in Toronto. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab150-awards-its-second-drug-discovery-project-from-canadas-largest-research-based-hospital-the-university-health-network-uhn-5731

In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-7—kidney-diseases-20-5728

Evotec AG and  Almirall, S.A. today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-almirall-enter-into-research-collaboration-in-the-field-of-dermatological-diseases-5725

Evotec AG announced today that Evotec and Celgene Corporation (“Celgene”) have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-enter-partnership-in-the-field-of-targeted-protein-degradation-5721

Evotec AG announced today that its shares will be included in the MDAX as of 24 September 2018 as announced by Deutsche Börse on 05 September 2018. This dual listing of the Evotec shares in both TecDAX and MDAX results from the rule changes regarding the inclusion of companies in the MDAX, SDAX and TecDAX. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-listed-in-mdax-5723

Evotec AG today announced that CHDI Foundation, Inc. (“CHDI”) has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec’s best-in-class integrated neuroscience platform. The extension of this collaboration is a further validation of Evotec’s investment in new technologies and capabilities in support of driving innovative drug discovery collaborations.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-chdi-foundation-extend-ongoing-collaboration-to-fight-huntingtons-disease-5717